# Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

> **NCT03992846** · PHASE3 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 486 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** 75 mg linzagolix tablet
- **DRUG:** 200 mg linzagolix tablet
- **DRUG:** Add-back capsule (E2 1 mg / NETA 0.5 mg)
- **DRUG:** Placebo tablet to match 75 mg linzagolix tablet
- **DRUG:** Placebo tablet to match 200 mg linzagolix tablet
- **DRUG:** Placebo capsule to match Add-back capsule

## Key facts

- **NCT ID:** NCT03992846
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-13
- **Primary completion:** 2021-10-18
- **Final completion:** 2022-04-01
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992846, "Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03992846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*